Cryoport (CYRX) Remains Unprofitable as Negative Margins Persist, Underscoring Ongoing Profitability Concerns

Cryoport (CYRX) remains unprofitable, with its net profit margin in negative territory and forecasts indicating continued losses over the next three years. Revenue is expected to grow at 8% per year, which is below the broader US market’s 10.5% pace. The company has managed to reduce its losses over the past five years at an annual rate of 1.6%. In this environment, investors are weighing persistent challenges in profitability and muted growth against a comparatively attractive valuation multiple.

See our full analysis for Cryoport.

The real test is how these numbers stack up against the prevailing market narratives. Let’s see where the current results confirm expectations and where they raise new questions.

See what the community is saying about Cryoport

Gross Margin Pushes Toward 50%

• Cryoport’s gross margin sits at 47%, with management explicitly targeting an increase to over 55% as the business scales and commercial contracts grow.
• Consensus narrative suggests that strategic partnerships, particularly with DHL, and investments in proprietary technologies like IntegriCell are expected to broaden Cryoport’s competitive edge and support higher gross margins.
  • Partnerships and proprietary launches enable Cryoport to seek premium pricing, pushing toward that 55% plus margin target.
  • Diversified revenues from BioStorage/BioServices and animal health, growing 28% year over year in those sub-segments, support longer-term margin durability even as cell and gene therapy markets fluctuate.

Price-to-Sales Discount vs. Peers

• Cryoport trades at a Price-to-Sales ratio of 1.8x, a significant discount to both the US Life Sciences industry average (3.4x) and the peer average (3.3x).
• Consensus narrative notes that this valuation gap reflects investor skepticism about Cryoport’s near-term unprofitability and below-market revenue forecasts.
  • Bears argue that, with no clear path to profitability in the next three years and negative share price momentum over the last quarter, the valuation gap could persist unless Cryoport accelerates improvements in margin or revenue growth.
  • However, the relative valuation may be compelling for investors focused on long-term contracts and scale benefits that are not yet fully visible in headline results.

Analyst Price Target Signals Upside

• At an $8.53 share price, the analyst consensus price target of $13.22 implies potential upside of approximately 55% if future revenue and profitability forecasts hold true.
• Consensus narrative highlights the tension: this upside assumes that by 2028, Cryoport achieves a profit margin increase from -21% to the industry average of 14.2%, reaches $206 million in revenues, and trades on a future PE ratio of 27.2x.
  • Analysts also model a modest annual increase (1.29%) in shares outstanding, meaning sustained growth and margin improvement are key to meeting these lofty targets.
  • The price target disconnect reflects disagreement among analysts, with bullish projections running as high as $16.00 and bearish calls as low as $8.00, all relying on those future operational milestones.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Cryoport on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Have your own take on the data? It only takes a couple of minutes to share your perspective and shape your narrative. Do it your way

A great starting point for your Cryoport research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.

See What Else Is Out There

Cryoport’s ongoing unprofitability and below-market revenue growth raise concerns about reliability and consistent value creation compared to its peers.

If you’re looking for steadier performers, check out stable growth stocks screener (2073 results) to target companies that deliver predictable growth and resilience through all market cycles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com